|
|
Blood, 1 October 2006, Vol. 108, No. 7, pp. 2407-2415.
Prepublished online as a Blood First Edition Paper on June 8, 2006; DOI 10.1182/blood-2006-04-020305.
Previous Article | Table of Contents | Next Article 
NEOPLASIA
Autocrine release of interleukin-9 promotes Jak3-dependent survival of ALK+ anaplastic large-cell lymphoma cells
Lin Qiu,
Raymond Lai,
Quan Lin,
Esther Lau,
David M. Thomazy,
Daniel Calame,
Richard J. Ford,
Larry W. Kwak,
Robert A. Kirken, and
Hesham M. Amin
From the Departments of Hematopathology and Lymphoma/Myeloma, University of Texas M. D. Anderson Cancer Center, Houston, TX; Department of Laboratory Medicine and Pathology and Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada; and Department of Biological Sciences, University of Texas at El Paso, El Paso, TX.
The aberrant fusion protein NPM-ALK plays an important pathogenetic role in ALK+ anaplastic large-cell lymphoma (ALCL). We previously demonstrated that Jak3 potentiates the activity of NPM-ALK. Jak3 activation is restricted to interleukins that recruit the common chain ( c) receptor, including IL-9. NPM-ALK was previously shown to promote widespread lymphomas in IL-9 transgenic mice by unknown mechanisms. We hypothesized that IL-9 plays an important role in ALK+ ALCL via Jak3 activation. Our studies demonstrate the expression of IL-9R and IL-9 in 3 ALK+ ALCL-cell lines and 75% and 83% of primary tumors, respectively. IL-9 was detected in serum-free culture medium harvested from ALK+ ALCL-cell lines, supporting autocrine release of IL-9. Treatment of these cells with an antiIL-9neutralizing antibody decreased pJak3 and its kinase activity, along with pStat3 and ALK kinase activity. These effects were associated with decreased cell proliferation and colony formation in soft agar and cell-cycle arrest. Evidence suggests that cell-cycle arrest can be attributed to up-regulation of p21 and down-regulation of Pim-1. Our results illustrate that IL-9/Jak3 signaling plays a significant role in the pathogenesis of ALK+ ALCL and that it represents a potential therapeutic target for treating patients with ALK+ ALCL.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
H. M. Amin and R. Lai
Pathobiology of ALK+ anaplastic large-cell lymphoma
Blood,
October 1, 2007;
110(7):
2259 - 2267.
[Abstract]
[Full Text]
[PDF]
|
 |
|
| |